guttiferone F | 219538-86-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: guttiferone F
• CAS: 219538-86-0
• 化学式: C₃₈H₅₀O₆
• 分子量: 602.811
• InChiKey: QDKLRKZQSOQWJQ-LPEHXNHASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.91
• 重原子数：
  44.0
• 可旋转键数：
  11.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  111.9
• 氢给体数：
  3.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  guttiferone F 在 1,1-二苯-2-苦基肼 作用下， 以 甲苯 为溶剂， 反应 24.0h， 以9.0 mg的产率得到garcimultiorone J
  参考文献：
  名称：

  Prenylated benzoylphloroglucinols and biphenyl derivatives from the leaves of Garcinia multiflora Champ

  摘要：

  Garcimultiflorone I (2) 从多花甘草叶中分离出来，对人类 SGC7901 和 HCT116 细胞株具有显著的抑制活性，通过细胞凋亡信号通路靶向细胞周期。

  DOI：

  10.1039/c5ra09213b

文献信息

• Guttiferone F, the First Prenylated Benzophenone from <i>Allanblackia stuhlmannii</i>
  作者：Richard W. Fuller、John W. Blunt、Jamie L. Boswell、John H. Cardellina、Michael R. Boyd

  DOI：10.1021/np9801514

  日期：1999.1.1

  The HIV-inhibitory activity in extracts of Allanblackia stuhlmannii was tracked, via bioassay-guided fractionation, to a new member of the camboginol/guttiferone class of prenylated benzophenones, guttiferone F (1). The structure was solved by extensive NMR analyses and by acid-catalyzed conversion to 30-epi-cambogin (4). This is the first report of this compound type in the genus Allanblackia.

  通过生物测定指导分级分离，追踪尿囊乌兰提取物中的HIV抑制活性，使其成为异戊二烯/ guttiferone类异戊二烯基二苯甲酮的新成员guttiferone F（1）。该结构通过广泛的NMR分析和酸催化转化为30-表cambogingin（4）得以解析。这是Allanblackia属中这种化合物类型的首次报道。
• Polyisoprenylbenzophenone derivatives, processes for their preparation and use thereof
  申请人：Aventis Pharma Deutschland Gmbh

  公开号：US20040082662A1

  公开（公告）日：2004-04-29

  The present invention relates to compounds of the formula (I) 1 which are produced by the plant Garcinia punctata, chemical derivatives derived therefrom, a process for their preparation, and their use as pharmaceuticals, in particular for the treatment and/or prophylaxis of bacterial infectious diseases.

  本发明涉及式 (I) 的化合物 1 的化合物。 刺芹、 的化学衍生物、其制备方法，以及它们作为药物的用途，特别是用于治疗和/或预防细菌性传染病。
• POLYISOPRENYL-BENZOPHENON-DERIVATE, VERFAHREN ZU IHRER HERSTELLUNG UND VERWENDUNG DERSELBEN
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1529025A1

  公开（公告）日：2005-05-11
• ANTI-PROSTATE CANCER COMPOUND AND METHOD OF USE THEREOF
  申请人：Hong Kong Baptist University

  公开号：US20150025155A1

  公开（公告）日：2015-01-22

  Prostate cancer is the most commonly diagnosed cancer in males and one of the leading causes of cancer death. Although treatment options have increased for some patients, overall progress has been modest. Thus, there is a great need to develop new treatments. This invention relates to a method for treating cancer comprising using an anti-cancer compound. More particularly, it relates to an anti-prostate cancer compound that can be isolated from Garcinia esculenta or chemically synthesized and its specific anticancer/antitumor activity. The invention has a specific application in treating human prostate cancer.
• METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE
  申请人：Design Therapeutics, Inc.

  公开号：US20210284629A1

  公开（公告）日：2021-09-16

  The present disclosure relates to compounds and methods for modulating the expression ofc9orf72 (brain expressed, associated with NEDD4) and treating diseases and conditions in which c9orf72 plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence GGGGCC; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence GGGGCC; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.